Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PPP5C | P53041 | 2/20 | 0.40 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.40 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13808561 | 0.90 | HTT (0.59) | HTTHRH3LMNAPOLBALDH1A1 | |
| SCHEMBL14453911 | 0.90 | HRH3 (0.60) | HRH3ALDH1A1TSHR | |
| SCHEMBL18704924 | 0.86 | HPGD (0.52) | HTTHRH3LMNAALDH1A1TSHR | |
| SCHEMBL26170519 | 0.85 | HRH3 (0.49) | HTTHRH3LMNAALDH1A1TSHR | |
| SCHEMBL14472444 | 0.83 | HRH3 (0.57) | HTTHRH3LMNAALDH1A1TSHR | |
| SCHEMBL14471383 | 0.83 | HRH3 (0.60) | HTTHRH3LMNAALDH1A1TSHR | |
| SCHEMBL26170628 | 0.83 | HSD11B1 (0.58) | HRH3POLBALDH1A1KMT2A | |
| SCHEMBL26170503 | 0.82 | HRH3 (0.49) | HRH3ALDH1A1TSHRKMT2A | |
| SCHEMBL25872062 | 0.82 | CHRNB2 (0.58) | HRH3ALDH1A1TSHRKMT2A | |
| SCHEMBL26173080 | 0.81 | PIK3CD (0.50) | HRH3LMNAALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023088477-A1 | MULTIFUNCTIONAL COMPOUND CAPABLE OF DEGRADING BTK KINASE, AND COMPOSITION AND USE | 杭州和正医药有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-7238694-B2 | Rifamycin imino derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | EGFR, ERBB2, ERBB3 | HTT 4270/4885HRH3 4374/4885LMNA 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.